Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Neuralstem Appoints CEO

This article was originally published in Scrip

Executive Summary

Neuralstem, a company focused on therapies for the central nervous system, has appointed Richard J. Daly president, CEO and a member of the company's board of directors. Daly has more than 25 years' experience and will succeed Richard Garr, J.D., who was president and CEO since co-founding Neuralstem. Recently, Dale was managing director of Ravine Rock Partners, LLC. and interim chief commercial officer at Catalyst Pharma until Sept. 2015. He also led the turnaround initiatives of the Bristol-Myers Squibb and AstraZeneca plc's diabetes alliance whilst serving as president of the US diabetes subsidiary from 2013 through the AstraZeneca integration completion in 2014.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel